OTCPK:ANPC.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products.


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has ANGLE's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ANPC.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

ANPC.F

-0.2%

US Medical Equipment

3.0%

US Market


1 Year Return

n/a

ANPC.F

14.8%

US Medical Equipment

15.8%

US Market

Return vs Industry: Insufficient data to determine how ANPC.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how ANPC.F performed against the US Market.


Shareholder returns

ANPC.FIndustryMarket
7 Day0%-0.2%3.0%
30 Dayn/a8.5%6.0%
90 Dayn/a10.7%16.4%
1 Yearn/a15.8%14.8%18.4%15.8%
3 Yearn/a75.5%70.7%44.8%35.4%
5 Yearn/a118.0%101.1%75.7%56.7%

Price Volatility Vs. Market

How volatile is ANGLE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ANGLE undervalued compared to its fair value and its price relative to the market?

3.02x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ANPC.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ANPC.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ANPC.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: ANPC.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANPC.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANPC.F is good value based on its PB Ratio (3x) compared to the US Medical Equipment industry average (4.2x).


Next Steps

Future Growth

How is ANGLE forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ANGLE has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine ANGLE's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access ANGLE's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has ANGLE performed over the past 5 years?

-19.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ANPC.F is currently unprofitable.

Growing Profit Margin: ANPC.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANPC.F is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.

Accelerating Growth: Unable to compare ANPC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANPC.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).


Return on Equity

High ROE: ANPC.F has a negative Return on Equity (-30.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is ANGLE's financial position?


Financial Position Analysis

Short Term Liabilities: ANPC.F's short term assets (£23.6M) exceed its short term liabilities (£2.4M).

Long Term Liabilities: ANPC.F's short term assets (£23.6M) exceed its long term liabilities (£1.6M).


Debt to Equity History and Analysis

Debt Level: ANPC.F is debt free.

Reducing Debt: ANPC.F had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANPC.F has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ANPC.F has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 23.9% each year.


Next Steps

Dividend

What is ANGLE current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANPC.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANPC.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANPC.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANPC.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANPC.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Andrew David Newland (58 yo)

no data

Tenure

UK£244,000

Compensation

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu ...


CEO Compensation Analysis

Compensation vs Market: Andrew David's total compensation ($USD320.33K) is below average for companies of similar size in the US market ($USD606.98K).

Compensation vs Earnings: Andrew David's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Andrew David Newland
Founderno dataUK£244.00k4.09%
£ 4.9m
Ian Griffiths
CFO, Finance Director16.42yrsUK£153.00k0.39%
£ 470.6k
Madeline Repollet
Head of Clinical Laboratories0.17yrno datano data
Paul Smith
VP & Chief Executive Officer of ANGLE Biosciences Inc2.75yrsno datano data
Martin Cooke
Director of Manufacturing & Regulatory Affairs2.58yrsno datano data
Michael O'Brien
Business Development Director6.75yrsno datano data

2.8yrs

Average Tenure

55yo

Average Age

Experienced Management: ANPC.F's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Andrew David Newland
Founderno dataUK£244.00k4.09%
£ 4.9m
Ian Griffiths
CFO, Finance Director16.42yrsUK£153.00k0.39%
£ 470.6k
Harold Swerdlow
Member of Scientific Advisory Boardno datano datano data
Garth Selvey
Non-Executive Chairman12.92yrsUK£17.00k0.012%
£ 14.0k
Ashok Venkitaraman
Member of Scientific Advisory Boardno datano datano data
Brian Howlett
Non- Executive & Senior Independent Director1.58yrsUK£17.00k0.0058%
£ 7.0k
Clive Stanway
Member of Scientific Advisory Boardno datano datano data
Adrian Newland
Member of Scientific Advisory Boardno datano datano data
George Hvichia
Member of Scientific Advisory Board2.58yrsno datano data
James Reuben
Member of Scientific Advisory Board5.17yrsno datano data
Daniel Danila
Member of Scientific Advisory Board5.08yrsno datano data
Greg Shaw
Member of Scientific Advisory Boardno datano datano data

5.2yrs

Average Tenure

58yo

Average Age

Experienced Board: ANPC.F's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ANGLE plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ANGLE plc
  • Ticker: ANPC.F
  • Exchange: OTCPK
  • Founded: 1994
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£91.867m
  • Listing Market Cap: UK£120.605m
  • Shares outstanding: 172.68m
  • Website: https://www.angleplc.com

Number of Employees


Location

  • ANGLE plc
  • Surrey Research Park
  • 10 Nugent Road
  • Guildford
  • Surrey
  • GU2 7AF
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGLAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2004
ANPC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2004
DWVDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2004
ANPC.YOTCPK (Pink Sheets LLC)SPONSONRED ADRUSUSDOct 2014

Biography

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor ce ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/06 23:37
End of Day Share Price2020/07/14 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.